3-Hydroxy-3-methylglutaryl-coenzyme A reductase mRNA in Alzheimer and control brain

Statins are widely used pharmaceutical agents which lower plasma cholesterol by inhibiting the rate controlling enzyme 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase. One epidemiological study suggests that statin therapy may provide protection against Alzheimer disease (AD). The aim of the present study was to determine the relative expression of HMG-CoA reductase mRNAs in various areas of brain as well as in peripheral organs and to compare values in AD and control cases. High levels of the mRNA were found in all areas of brain but no obvious differences were found between AD and controls. We conclude that brain has a robust capacity to synthesize cholesterol which appears to be unaffected by AD pathology.

[1]  G. Eckert,et al.  Differential effects of lovastatin treatment on brain cholesterol levels in normal and ApoE-deficient mice , 2001, Neuroreport.

[2]  R. Haley,et al.  Is there a connection between the concentration of cholesterol circulating in plasma and the rate of neuritic plaque formation in Alzheimer disease? , 2000, Archives of neurology.

[3]  G. Celesia,et al.  Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.

[4]  H. Itakura,et al.  Gene expression related to cholesterol metabolism in mouse brain during development , 2000, Brain and Development.

[5]  A. Fagan,et al.  Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[6]  S. Paul,et al.  Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[7]  D J Stephens,et al.  The role of cholesterol in the biosynthesis of beta-amyloid. , 1999, Neuroreport.

[8]  P. Mcgeer,et al.  Up-regulated production and activation of the complement system in Alzheimer's disease brain. , 1999, The American journal of pathology.

[9]  P. Mcgeer,et al.  Human heart generates complement proteins that are upregulated and activated after myocardial infarction. , 1998, Circulation research.

[10]  J. Wahren,et al.  Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. , 1998, Journal of lipid research.

[11]  B. Strooper,et al.  Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[12]  John Q. Trojanowski,et al.  Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease , 1997, Neurobiology of Aging.

[13]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[14]  K. Kristensson,et al.  Rates of cholesterol, ubiquinone, dolichol and dolichyl‐P biosynthesis in rat brain slices , 1990, FEBS letters.

[15]  R. Mahley,et al.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.

[16]  A. Lossinsky,et al.  172 CYTOCHEMICAL AND ULTRASTRUCTURAL CHARACTERIZATION OF DEVELOPING BLOOD-BRAIN BARRIER (BBB) , 1984 .

[17]  F. Chevallier,et al.  Time course of biosynthetic cholesterol in the adult rat brain. , 1973, Biochimica et biophysica acta.

[18]  S. Holm.  A Simple Sequentially Rejective Multiple Test Procedure , 1979 .